Skip to main content
Premium Trial:

Request an Annual Quote

Ocimum Biosolutions to Offer NuGen's Ovation System in India

NEW YORK (GenomeWeb News) — Ocimum Biosolutions has become authorized by NuGen to provide sample preparation services in India using NuGen’s Ovation Systems, Hyderabad, India-based Ocimum said today.
Ocimum said it will now be able to offer the Ovation service to researchers who are conducting gene expression profiling studies from a range of sample types, such as small, compromised, or formalin-fixed, paraffin-embedded tissues.
NuGen representatives will provide Ocimum with specialized training to ensure their proficiency in generating high quality data from customer samples. The two companies also will work together to develop additional resources for customers including online seminars and technology updates.
The Ovation Systems are designed to be used in a range of sample types, including FFPE tissues, whole blood, tissue biopsies, later-captured micro-dissected cells, and sorted cells.
“With India's rapidly growing number of partnerships with global pharma companies, our alliance will significantly contribute to the success of customers' development and collaboration programs,” Sue Pandey, VP of field operations for San Carlos, Calif.-based NuGen, said in a statement.
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.